This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

16 May 2012

Pharma Consortium Provides £14.4M Funding for Drug Discovery

The DSTT consortium has attracted new investment which will enable its vital drug discovery work to continue until at least 2016.

A consortium of six pharmaceutical companies is providing more than £14 million for the development of new drug treatments for major diseases.


The £14.4 million funding, which was announced by the UK's Medical Research Council (MRC) and the University of Dundee, will be provided over a four-year period by the Division of Signal Transduction Therapy (DSTT).


This is comprised of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Janssen Pharmaceutica NV, Merck-Serono and Pfizer, along with 15 research teams at the University of Dundee, and is thought to be the world's largest academia-pharma collaboration.


Thanks to the new funding, scientists will be able to continue early-stage research in a

Related News